Overview of R&D Activities

CHUGAI PHARMACEUTICAL CO., LTD.
Senior Vice President
Head of Strategic Marketing Unit and
General Manager of Strategic Planning Dept.
Tatsuro Kosaka

January 30/31, 2008
Forward Looking Statements

This presentation may include forward looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.
R&D Topics  (October 2007 ~ January 2008)

2007

- **Nov**  MRA (Actemra) : Filed application for rheumatoid arthritis in United States and Europe (Roche)
- **Dec**  R340 (Xeloda) : Approved and launched for additional indication of monotherapy treatment in adjuvant colon cancer and global dosage and administration for breast cancer
- **Dec**  R1415(Tarceva) : Approved and launched for non-small cell lung cancer
- **Dec**  R1594 : Joined multinational phase III study with Roche/Genentech for rheumatoid arthritis
- **Dec**  EPOCH(Epogen) : Withdrew the application for additional dosage and administration for renal anemia in hemodialysis patients
# Projects under Development (as of Jan 2008)

## Oncology
- **R1273 (NSCLC)**
- **TP300 (CRC)**
- Actemra (multiple myeloma)
- Xeloda (CRC/combo)
- Avastin (NSCLC)
- Avastin (BC)
- Tarceva (PC)
- R744 (Mircera CIA)
- **Herceptin (Adj. BC)#**
- **Epogen (CIA)**
- **Avastin (Adj. CC)#**
- **Avastin (GC)#**
- **Herceptin (GC)#**
- **Xeloda (GC)**

## Bone & Joint
- **R484 (Bonviva iv osteoporosis)**
- **R484 (Bonviva oral osteoporosis)**
- ED-71 (osteoporosis)
- Actemra (sJIA)
- R1594 (RA)
- **Actemra (RA)**
- **Actemra (sJIA)**

## Renal
- **R744 (Mircera renal anemia)**

## Transplant, Immunology, Infection
- **Actemra (SLE)**
- **Actemra (castleman's disease)**
- **Actemra (crohn's disease)**
- **Pegasys / Copegus (liver cirrhosis)**
- **Pegasys (chronic hepatitis B)**
- **NA808 (chronic hepatitis C)**

## Others
- **GM-611 (diabetic gastroparesis)**
- **R1678 (schizophrenia)**
- **R1583 (type II diabetes)**
- **CSG452 (type II diabetes)**
- **AVS (subarachnoidal hemorrhage)**
- **Epogen (autologous transfusion)**

*GM-611 is being considered for out-licensing

*Italic: Roche projects, Underlined: overseas’ clinical development, #: participation in multi-national studies*
Projected Submissions

Filings planned each year

Launched

- COPEGUS HCV
- AVASTIN CRC
- TARCEVA NSCLC
- XELODA Adj.CC
- HERCEPTIN Adj.BC
- ACTEMRA RA, sJIA
- ACTEMRA RA/Overseas
- AVASTIN NSCLC
- MIRCERA Renal Anemia
- XELODA CRC
- ED-71 Osteoporosis
- HERCEPTIN GC
- BONVIVA Osteoporosis
- AVASTIN GC
- AVASTIN Adj.CC
- AVASTIN Liver Cirrhosis
- PEGASYS HBV
- R1594 RA
- PEG/COPE Liver Cirrhosis
- XELODA GC
- TACIEVA PC
- HERCEPTIN GC

~ 2007 2008 2009 2010 2011 ~ 2013

- New molecular entity
- Additional indication etc.
- In-licensed from Roche
Contacts:

Corporate Communications Group
Tel: +81 (0)3-3273-0881  Fax: +81 (0)3-3281-6607
e-mail: pr@chugai-pharm.co.jp
Masayuki Yamada, Seiji Shimada, Hiroshi Araki

Investor Relations Group
Tel: +81 (0)3-3273-0554  Fax: +81 (0)3-3281-6607
e-mail: ir@chugai-pharm.co.jp
Mac Uchida, Kae Maeda, Tomoko Shimizu, Yusuke Tokita